Hormone Replacement and Breast CancerThere are dozens of studies regarding the "safe" use of hormones to control menopausal symptoms and control disease progression.
Certainly, and foremost, breast cancer development is on every ones mind when it comes to HRT administration. It is important to point out that there are numerous controlled studies to date that to contradict that point, in fact, we now feel with stronger scientific evidence, that poor lifestyle habits combined with secondary hormonal deficiencies (like progesterone), and bad estrogens that may be leading towards malignant and / or benign breast disease.
Ongoing studies are in place in-particular to "natural hormone use." So far most outcomes of these studies seem positive and are deemed beneficial when it comes to treatment of hot flashes, vaginal dryness, low libido, osteoporosis, heart disease, diabetes and mood disturbances.
We must conclude however that Hormone replacement therapy needs to be monitored closely by your physician or practitioner and must obtain yearly physical, blood work and scheduled mammogram sudies.
Please review links below and browse through literature.. we will be adding more links and reference sources monthly for your review. Education is power!
G. Ursin, S. London, D. Yang, C. C. Tseng, M. C. Pike, L. Bernstein, F. Z. Stanczyk, and E. Gentzschein. Urinary 2-hydroxyestrone/16alpha- hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast Cancer Res Treat 72 (2):139-143, 2002.
R. T. Falk, T. R. Fears, X. Xu, R. N. Hoover, M. C. Pike, A. H. Wu, A. M. Nomura, L. N. Kolonel, D. W. West, D. W. Sepkovic, H. L. Bradlow, and R. G. Ziegler. Urinary estrogen metabolites and their ratio among Asian American women. Cancer Epidemiol.Biomarkers Prev. 14 (1):221-226, 2005.
Greenlee, Y. Chen, G. C. Kabat, Q. Wang, M. G. Kibriya, I. Gurvich, D. W. Sepkovic, H. L. Bradlow, R. T. Senie, R. M. Santella, and H. Ahsan. Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer. Breast Cancer Res Treat. 102 (1):111-117, 2007.
Eliassen, S. A. Missmer, S. S. Tworoger, and S. E. Hankinson. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol.Biomarkers Prev. 17 (8):2029-2035, 2008.
Obi, A. Vrieling, J. Heinz, and J. Chang-Claude. Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16alpha-hydroxyestrone ratio predictive for breast cancer? Int.J Womens Health 3:37-51, 2011?